AbstractBackground Previous reports

Abstract
Background Previous reports have demonstrated an
association between chronic inflammation with metabolic
syndrome (MS) and cardiovascular risk factors.
Aim As lichen planus (LP) is a chronic inflammatory
disease, the purpose of this study was to assess the
prevalence of MS, dyslipidemia, insulin resistance and
obesity in LP patients.
Methods A total of 79 patients with LP and 79 controls
were examined in this case–control study. Both groups
were evaluated for the presence of MS, dyslipidemia,
obesity and insulin resistance, and other cardiovascular risk
factors. Erythrocyte sedimentation rate, fibrinogen and
C-reactive protein were measured as inflammation
markers.
Results The prevalence of MS was significantly higher in
the patients with LP than in controls (26.6 vs. 12.7 %;
P = 0.045). It was also significantly higher in LP patients
with mucosal involvement than without (34.5 vs. 8.3 %;
P = 0.032). Among the MS criteria, mean fasting blood
glucose and diastolic blood pressure were also significantly
higher in LP patients than in controls (P = 0.012 and
P = 0.021, respectively). No significant differences
between LP patients and controls were observed with
respect to prevalence of dyslipidemia and insulin resistance
(P = 0.866 and P = 1.000, respectively). However, duration
of disease was significantly longer in patients with
insulin resistance than in those without (P = 0.034).
Conclusions The patients with LP, particularly those with
mucosal involvement, have a higher prevalence of MS,
which is associated with a risk for cardiovascular diseases
and diabetes mellitus.

ผลลัพธ์ (อังกฤษ) 2:

Abstract
Background Previous reports have demonstrated an
association between chronic inflammation with metabolic
Syndrome (MS) and cardiovascular risk factors.
Aim As Lichen planus (LP) is a chronic inflammatory
disease, the purpose of this Study was to assess the
prevalence of MS, dyslipidemia,. insulin resistance and
obesity in Patients LP.
Methods A total of 79 Patients with Controls LP and 79
were examined in this Case-Control Study. Both groups
were evaluated for the Presence of MS, dyslipidemia,
obesity and insulin resistance, and cardiovascular risk Other
factors. Erythrocyte sedimentation rate, fibrinogen and
C-reactive protein were measured As inflammation
Markers.
Results The prevalence of MS was significantly Higher in
Patients with the LP than in Controls (26.6 vs. 12.7%;
P = 0.045). It was also significantly Higher in LP Patients
with mucosal involvement than without (34.5 vs. 8.3%;
P = 0.032). Among the MS criteria, Mean fasting blood
glucose and diastolic blood pressure were also significantly
Higher in Patients LP than in Controls (P = 0.012 and
P = 0.021, respectively). No significant differences
were observed between LP Patients and Controls with
prevalence of dyslipidemia and insulin resistance Respect to
(P = 0.866 and P = 1.000, respectively). However, Duration
of disease was significantly Longer in Patients with
insulin resistance than in those without (P = 0.034).
Conclusions The Patients with LP, particularly those with
mucosal involvement, have a Higher prevalence of MS,
which is associated with a risk for cardiovascular. diseases
and Diabetes mellitus.